Randomised Trial of Anti-CD20 in C4d+ Chronic Allograft Nephropathy
Read time: 1 mins
Last updated:16th Oct 2006
To determine whether anti-CD20 therapy can stabilise or improve renal function and/or proteinuria in patients with C4d+, chronic (humoral) rejection in whom standard therapeutic approaches have failed.
|Study start date||2006-10-16|